Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/personalized-mrna-cancer-vaccines.md — the filesystem corpus, unchanged. Not an edit.
18.9 kB
Revision 1
Revision 2
lines 8–14 → 8–147 unchanged lines not shown
categories: ["genetics", "longevity"]categories: ["genetics", "longevity"]tags: ["cancer", "mrna", "immunotherapy", "neoantigens", "melanoma", "oncology", "vaccines"]tags: ["cancer", "mrna", "immunotherapy", "neoantigens", "melanoma", "oncology", "vaccines"]summary: "A therapy in which one patient's tumour is sequenced, its mutation-derived antigens are ranked by algorithm, and a synthetic mRNA encoding them is manufactured for that person alone."summary: "A therapy in which one patient's tumour is sequenced, its mutation-derived antigens are ranked by algorithm, and a synthetic mRNA encoding them is manufactured for that person alone."updated: "2026-08-22"updated: "2026-08-23"humanEvidence: "A randomised phase 3 in 1,137 people with resected melanoma met its recurrence-free survival endpoint according to its sponsors, who released no hazard ratios; overall survival is unreported from it and only exploratory in the phase 2b behind it."humanEvidence: "A randomised phase 3 in 1,137 people with resected melanoma met its recurrence-free survival endpoint according to its sponsors, who released no hazard ratios; overall survival is unreported from it and only exploratory in the phase 2b behind it."access: "Available only inside company-run clinical trials; no individualized neoantigen therapy is approved by any regulator as of August 2026, and no price has been announced."access: "Available only inside company-run clinical trials; no individualized neoantigen therapy is approved by any regulator as of August 2026, and no price has been announced."reversibility: "partly-reversible"reversibility: "partly-reversible"lines 44–49 → 44–5329 unchanged lines not shown
## How it works## How it works A neoantigen is a protein fragment that exists only because a tumour mutated. It is absent from every healthy cell, which makes it a target the immune system can attack without attacking the patient. The difficulty is that neoantigens are almost entirely private to one tumour, so there is nothing to stock on a shelf.A neoantigen is a protein fragment that exists only because a tumour mutated. It is absent from every healthy cell, which makes it a target the immune system can attack without attacking the patient. The difficulty is that neoantigens are almost entirely private to one tumour, so there is nothing to stock on a shelf. ```figure{"key": "mrna-vaccine-mechanism", "caption": "The shared platform: lipid-nanoparticle delivery and translation in the recipient's cells. The per-patient step — choosing which 34 mutations the mRNA encodes — happens before this diagram begins."}``` The workflow answers that by manufacturing per patient. A biopsy and a blood sample are sequenced and compared, separating the tumour's mutations from the person's inherited variation. An algorithm then scores those mutations for the chance that a fragment carrying them will be displayed on the cell surface by that patient's own major histocompatibility complex molecules and recognised by a T cell. Moderna's product, intismeran autogene, encodes up to 34 of the top-ranked mutations in a single synthetic mRNA, made as a single-patient batch at the company's Massachusetts facilities and shipped to the trial site for intramuscular injection.[^moderna2026] The antigens are translated inside the recipient's cells rather than injected as peptides, so they enter the normal antigen-processing pathway.The workflow answers that by manufacturing per patient. A biopsy and a blood sample are sequenced and compared, separating the tumour's mutations from the person's inherited variation. An algorithm then scores those mutations for the chance that a fragment carrying them will be displayed on the cell surface by that patient's own major histocompatibility complex molecules and recognised by a T cell. Moderna's product, intismeran autogene, encodes up to 34 of the top-ranked mutations in a single synthetic mRNA, made as a single-patient batch at the company's Massachusetts facilities and shipped to the trial site for intramuscular injection.[^moderna2026] The antigens are translated inside the recipient's cells rather than injected as peptides, so they enter the normal antigen-processing pathway. removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
128 lines are the same in both revisions, and 116 of them are not shown. Neither revision here is necessarily the current article — read Personalized mRNA cancer vaccines for the text this wiki stands behind today.